Personalized Medicine Partners - Mr. Michael Stocum
v: 1.919.740.6294
Mr. Michael Stocum is the Managing Director of Personalized Medicine Partners, a firm that supports companies seeking to create molecular medicine programs by integrating therapeutics and diagnostics through enhanced licensing, business and product development. Mr. Stocum was appointed to the American Association for Clinical Chemistry's Pharmacogenomics Advisory Group in 2003. He also serves on the North Carolina State University (NCSU) Professional Sciences Master's degree industry advisory board and in the Personalized Medicine Coalition, a non-profit dedicated to advancing the field of Personalized Medicine. His educational background includes dual B.S. degrees in Biochemistry and Microbiology plus an M.S. in Biotechnology Management all from North Carolina State University and included two years of academic and NIH research. Mr. Stocum has worked in life sciences for over 15 years including roles in both academia and industry.
He began his career in research, and then progressed to product, business, and commercial development positions in pharmaceuticals, biologics and molecular diagnostics. He was a Research Assistant at the National Institute for Environmental Health Sciences studying DNA strand repair and tumorigenesis. He held a Research Assistantship during his graduate studies North Carolina State University where he conducted mutational analysis in yeast physiology and sterol biosynthesis. Mr. Stocum joined Akzo-Nobel Pharma's Organon Teknika unit (OT). While there he supported Onco- Tice BCG, a bladder cancer biopharmaceutical. He was responsible for developing and launching assays to quantify HIV-1 RNA and conducted numerous studies that evaluated and expanded the utility of the product for treatment and management of HIV disease. He led and managed relationships with top tier investigators across North America and selected groups in Europe. He was also responsible for other molecular medicine testing products, and later, as International Pharmaceuticals Project Manager, he created and implemented business strategies and collaborations to develop novel pharmacodiagnostics.
Mr. Stocum joined GlaxoSmithKline in 2000 as Business Development & Alliance Management Director and developed strategies and implemented numerous molecular medicine programs (therapeutics combined with diagnostics and biomarkers). The research projects and business agreements he championed in Anti-infectives, Oncology, Metabolics and Cardiovascular resulting in accelerated development, improved product differentiation and market expansion for GSK's medicines. He was coleader of a research initiative to identify pharmacogenetic biomarkers from clinical trial participants to identify patients at risk for Hypersensitivity to Abacavir, a common drug in a variety of anti-HIV treatment regimens. The work resulted in a Lancet publication. Additionally, his work in oncology focused on biomarkers to predict response to the kinase inhibitor Tykerb®, approved by FDA in March 2007.
